Applied DNA Sciences regains compliance with Nasdaq minimum bid price rule

Applied DNA Sciences announced that on May 9, 2024, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously reported, the Company was notified on December 1, 2023, that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company’s ordinary shares needed to be at least $1.00 for a minimum of 10 consecutive business days. The Notification Letter confirmed that the Company evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for 10 consecutive business days from April 25, 2024, to May 8, 2024, and that the Company has regained compliance with the Minimum Bid Price Requirement.